Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | TACR1 | P25103 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.37 |
| ▸ | DPP4 | P27487 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1702211 | 0.92 | USP2 (0.38) | SMN1; SMN2USP2L3MBTL1ADORA1HPGD | |
| Piperidine SCHEMBL19995285 | 0.90 | HPGD (0.38) | SMN1; SMN2USP2L3MBTL1ADORA1HPGD | |
| SCHEMBL27426146 | 0.86 | USP2 (0.50) | SMN1; SMN2USP2HPGDTSHREPHX2 | |
| SCHEMBL2206945 | 0.85 | SMN1; SMN2 (0.46) | SMN1; SMN2USP2L3MBTL1ADORA1HPGD | |
| SCHEMBL1147479 | 0.84 | SMN1; SMN2 (0.45) | SMN1; SMN2USP2L3MBTL1ADORA1HPGD | |
| SCHEMBL442966 | 0.84 | SMN1; SMN2 (0.45) | SMN1; SMN2USP2L3MBTL1ADORA1HPGD | |
| SCHEMBL20011966 | 0.83 | USP2 (0.40) | SMN1; SMN2USP2L3MBTL1ADORA1HPGD | |
| SCHEMBL662017 | 0.83 | USP30 (0.42) | SMN1; SMN2USP2L3MBTL1ADORA1HPGD | |
| SCHEMBL2661172 | 0.83 | USP2 (0.47) | SMN1; SMN2USP2HPGDTSHREPHX2 | |
| SCHEMBL20565162 | 0.83 | USP2 (0.42) | SMN1; SMN2USP2L3MBTL1ADORA1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 189 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4695228-A1 | SYNTHESIS OF RAS INHIBITORS | Revolution Medicines, Inc. (US) | 2026-02-18 | — | — | EP | disclosed |
| EP-4682148-A2 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | AbbVie Ireland Unlimited Company (IE) | 2026-01-21 | — | — | EP | disclosed |
| EP-4680333-A1 | PHENYLPIPERIDINE DERIVATIVES AS INHIBITORS OF GLUTAMINYL-PEPTIDE CYCLOTRANSFERASE AND GLUTAMINYL-PEPTIDE CYCLOTRANSFERASE LIKE PROTEIN | Boehringer Ingelheim International GmbH (DE) | 2026-01-21 | — | — | EP | disclosed |
| US-20250250252-A1 | PIPERIDINYLBENZONITRILE DERIVATIVES AS INHIBITORS OF GLUTAMINYL-PEPTIDE CYCLOTRANSFERASE AND GLUTAMINYL-PEPTIDE CYCLOTRANSFERASE LIKE PROTEIN | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2025-08-07 | — | — | US | disclosed |
| US-20250250251-A1 | PIPERIDINYLPYRIDINYLCARBONITRILE DERIVATIVES AS INHIBITORS OF GLUTAMINYL-PEPTIDE CYCLOTRANSFERASE AND GLUTAMINYL-PEPTIDE CYCLOTRANSFERASE LIKE PROTEIN | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2025-08-07 | — | — | US | disclosed |
| US-20250161318-A1 | SOLID DISPERSIONS CONTAINING AN APOPTOSIS-INDUCING AGENT | ABBVIE INC (US) | 2025-05-22 | — | — | US | disclosed |
| US-20250059165-A1 | PIPERIDINYLPYRIDINYLCARBONITRILE DERIVATIVES AS INHIBITORS OF GLUTAMINYL-PEPTIDE CYCLOTRANSFERASE AND GLUTAMINYL-PEPTIDE CYCLOTRANSFERASE LIKE PROTEIN | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2025-02-20 | — | — | US | disclosed |
| US-20250059166-A1 | PIPERIDINYLPYRIDINYLCARBONITRILE DERIVATIVES AS INHIBITORS OF GLUTAMINYL-PEPTIDE CYCLOTRANSFERASE AND GLUTAMINYL-PEPTIDE CYCLOTRANSFERASE LIKE PROTEIN | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2025-02-20 | — | — | US | disclosed |
| US-20250026721-A1 | COMPOUNDS AND METHODS FOR MODULATING RAS-PI3K | VIVIDION THERAPEUTICS, INC. | 2025-01-23 | — | — | US | disclosed |
| US-20250019364-A1 | APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC. (US) | 2025-01-16 | — | — | US | disclosed |
| US-20080119487-A1 | NOVEL NON-IMIDAZOLE COMPOUNDS | SCHERING CORPORATION | 2008-05-22 | — | — | US | disclosed |
| US-20080058370-A1 | 1-[[1-[(2-Amino-6-methyl-4-pyridinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]piperidine and Methods of Use Thereof | SCHERING CORPORATION | 2008-03-06 | — | — | US | disclosed |
| US-7332604-B2 | 1-[[1-[(2-Amino-6-methyl-4-pyridinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]piperidine | SCHERING CORPORATION (US) | 2008-02-19 | — | — | US | disclosed |
| US-7300941-B2 | Non-imidazole compounds | SCHERING CORPORATION (US) | 2007-11-27 | — | — | US | disclosed |
| US-7300941-B2 | Non-imidazole compounds | SCHERING CORPORATION (US) | 2007-11-27 | — | — | US | disclosed |
| EP-1777223-A1 | Indole derivatives useful as histamine H3 antagonists | SCHERING CORPORATION (US) | 2007-04-25 | — | — | EP | disclosed |
| WO-2007035703-A1 | 1- [ [1- [ (2-AMIN0-6-METHYL-4-PYRIDINYL) METHYL] -4-FLU0R0-4-PIPERIDINYL,] CARBONYL] -4- [2- (2-PYRIDINYL) -3H-IMIDAZ0 [4 , 5-B] PYRIDIN-3-YL] PIPERIDINE USEFUL AS HISTAMINE H3 ANTAGONIST | SCHERING CORPORATION (US) | 2007-03-29 | — | — | WO | disclosed |
| US-20070066644-A1 | 1-[[1-[(2-Amino-6-methyl-4-pyridinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]piperidine | SCHERING CORPORATION | 2007-03-22 | — | — | US | disclosed |
| US-20070066644-A1 | 1-[[1-[(2-Amino-6-methyl-4-pyridinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]piperidine | SCHERING CORPORATION | 2007-03-22 | — | — | US | disclosed |
| WO-2007002884-A2 | 4-FLUORO-PIPERIDINE T-TYPE CALCIUM CHANNEL ANTAGONISTS | MERCK & CO., INC. (US) | 2007-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250250252-A1 | PIPERIDINYLBENZONITRILE DERIVATIVES AS INHIBITORS OF GLUTAMINYL-PEPTIDE CYCLOTRANSFERASE AND GLUTAMINYL-PEPTIDE CYCLOTRANSFERASE LIKE PROTEIN | QPCT, QPCTL, GLUL | SMN1; SMN2 4549/4885USP2 1806/4885L3MBTL1 788/4885 |
| US-20250026721-A1 | COMPOUNDS AND METHODS FOR MODULATING RAS-PI3K | KRAS, HRAS, NRAS | SMN1; SMN2 4430/4885USP2 627/4885L3MBTL1 3589/4885 |
| US-20250059166-A1 | PIPERIDINYLPYRIDINYLCARBONITRILE DERIVATIVES AS INHIBITORS OF GLUTAMINYL-PEPTIDE CYCLOTRANSFERASE AND GLUTAMINYL-PEPTIDE CYCLOTRANSFERASE LIKE PROTEIN | QPCT, QPCTL, GLUL | SMN1; SMN2 4484/4885USP2 2033/4885L3MBTL1 1188/4885 |
| US-20070066644-A1 | 1-[[1-[(2-Amino-6-methyl-4-pyridinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]piperidine | FABP1, GPR119, FABP4 | SMN1; SMN2 3477/4885USP2 4665/4885L3MBTL1 4229/4885 |
| US-20250019364-A1 | APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BCL2, BAX, BCL3 | SMN1; SMN2 2670/4885USP2 1141/4885L3MBTL1 973/4885 |
| US-20250161318-A1 | SOLID DISPERSIONS CONTAINING AN APOPTOSIS-INDUCING AGENT | BCL2, BAX, BCL2L1 | SMN1; SMN2 318/4885USP2 1360/4885L3MBTL1 1112/4885 |
| US-20250250251-A1 | PIPERIDINYLPYRIDINYLCARBONITRILE DERIVATIVES AS INHIBITORS OF GLUTAMINYL-PEPTIDE CYCLOTRANSFERASE AND GLUTAMINYL-PEPTIDE CYCLOTRANSFERASE LIKE PROTEIN | QPCT, QPCTL, GLUL | SMN1; SMN2 4484/4885USP2 2033/4885L3MBTL1 1188/4885 |
| US-20250059165-A1 | PIPERIDINYLPYRIDINYLCARBONITRILE DERIVATIVES AS INHIBITORS OF GLUTAMINYL-PEPTIDE CYCLOTRANSFERASE AND GLUTAMINYL-PEPTIDE CYCLOTRANSFERASE LIKE PROTEIN | QPCT, QPCTL, GLUL | SMN1; SMN2 4484/4885USP2 2033/4885L3MBTL1 1188/4885 |
| US-20080058370-A1 | 1-[[1-[(2-Amino-6-methyl-4-pyridinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]piperidine and Methods of Use Thereof | FABP1, LIPC, GPR119 | SMN1; SMN2 3775/4885USP2 4559/4885L3MBTL1 3855/4885 |
| US-20080119487-A1 | NOVEL NON-IMIDAZOLE COMPOUNDS | HRH2, HRH1, HRH4 | SMN1; SMN2 4797/4885USP2 3613/4885L3MBTL1 4809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.